Fig. 4: BCL-XL inhibition elevates AIF pathway levels resulting in a synergistic activity with MTIs.
From: Predicting and affecting response to cancer therapy based on pathway-level biomarkers
a Cartoon depicting the ‘AIF in apoptosis and cell-survival pathway’ with ABT-263 and MTI activity. b AIF pathway activity levels calculated from qRT-PCR in lung cancer cell lines before treatment (black bars), after treatment with ABT-263 (blue bars), and after treatment with a combination of vinorelbine and ABT-263 (gray bars). H211 was identified as sensitive, and the other four cell lines as not sensitive. Error bars represent the standard deviation. P-values were generated using Mann–Whitney U-test. c Relative growth of lung cancer cell lines over a 7-day period with no treatment (solid black line), vinorelbine (dotted blue line), ABT-263 (solid blue line), and a combination of vinorelbine and ABT-263 (dotted black line). Error bars represent the standard deviation. d Bliss analysis of drug synergy in cell lines treated with vinorelbine plus ABT-263. Bliss index < 0.5 represents synergism. Error bars represent the standard deviation. See also Supplementary Fig. 7a.
